Bempedoic acid: Ph III CLEAR Outcomes started

Esperion began the double-blind, placebo-controlled, international Phase III CLEAR Outcomes trial to evaluate 180 mg oral bempedoic acid once daily in about 12,600 statin-intolerant patients with hype...